Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Zynerba Pharmaceuticals, Inc. | a17-4135_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8K
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 9, 2017
ZYNERBA PHARMACEUTICALS, INC.
(Exact Name of Issuer as Specified in Charter)
Delaware |
|
001-37526 |
|
26-0389433 |
(State or Other Jurisdiction of |
|
(Commission |
|
(I.R.S. Employer |
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(Address of Principal Executive Offices)
(484) 581-7505
(Registrants Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a12 under the Exchange Act (17 CFR 240.14a12)
o Precommencement communications pursuant to Rule 14d2(b) under the Exchange Act (17 CFR 240.14d2(b))
o Precommencement communications pursuant to Rule 13e4(c) under the Exchange Act (17 CFR 240.13e4(c))
Item 8.01 Other Events.
On February 9, 2017, Zynerba Pharmaceuticals, Inc. (the Company) issued a press release announcing that the underwriters of its previously announced underwritten public offering of 2.8 million shares of its common stock at $18.00 per share have exercised in full their option to purchase an additional 420,000 shares of common stock at the public offering price less the underwriting discounts and commissions. A copy of this press release is attached hereto as Exhibit 99.1.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
Exhibit |
|
Document |
|
|
|
99.1 |
|
Press Release dated February 9, 2017. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 9, 2017 |
| |
|
| |
|
ZYNERBA PHARMACEUTICALS, INC. | |
|
| |
|
By: |
/s/ Suzanne Hanlon |
|
Name: |
Suzanne Hanlon |
|
Title: |
Secretary, General Counsel and |